Technical Analysis for KYTX - Kyverna Therapeutics, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | N/A | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Stochastic Buy Signal | Bullish | 0.00% | |
Lower Bollinger Band Walk | Weakness | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Gapped Up | Strength | 0.00% | |
Below Lower BB | Weakness | 0.00% | |
Lower Bollinger Band Touch | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
New 52 Week Closing Low | Bearish | 0.98% | |
Lower Bollinger Band Walk | Weakness | 0.98% | |
New 52 Week Low | Weakness | 0.98% |
Alert | Time |
---|---|
Rose Above Previous Day's High | about 19 hours ago |
Up 5% | about 19 hours ago |
60 Minute Opening Range Breakout | about 21 hours ago |
Up 3% | about 21 hours ago |
Gap Up Closed | about 22 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: Unknown
Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our lead product candidate, KYV-101 is advancing through clinical development across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for multiple sclerosis and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1 trials in the United States and Germany for patients with lupus nephritis.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Autoimmune Disease Autoimmunity Multiple Sclerosis Lupus Rheumatology Myasthenia Gravis Sjögren Syndrome Lupus Nephritis Systemic Sclerosis
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Autoimmune Disease Autoimmunity Multiple Sclerosis Lupus Rheumatology Myasthenia Gravis Sjögren Syndrome Lupus Nephritis Systemic Sclerosis
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 35.06 |
52 Week Low | 3.94 |
Average Volume | 347,528 |
200-Day Moving Average | 0.00 |
50-Day Moving Average | 5.28 |
20-Day Moving Average | 4.96 |
10-Day Moving Average | 4.81 |
Average True Range | 0.39 |
RSI (14) | 31.97 |
ADX | 16.56 |
+DI | 18.01 |
-DI | 30.30 |
Chandelier Exit (Long, 3 ATRs) | 4.51 |
Chandelier Exit (Short, 3 ATRs) | 5.12 |
Upper Bollinger Bands | 5.78 |
Lower Bollinger Band | 4.14 |
Percent B (%b) | -0.01 |
BandWidth | 32.98 |
MACD Line | -0.29 |
MACD Signal Line | -0.19 |
MACD Histogram | -0.0947 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 4.56 | ||||
Resistance 3 (R3) | 4.58 | 4.46 | 4.48 | ||
Resistance 2 (R2) | 4.46 | 4.35 | 4.45 | 4.46 | |
Resistance 1 (R1) | 4.29 | 4.28 | 4.23 | 4.27 | 4.43 |
Pivot Point | 4.17 | 4.17 | 4.14 | 4.16 | 4.17 |
Support 1 (S1) | 4.00 | 4.06 | 3.94 | 3.98 | 3.81 |
Support 2 (S2) | 3.88 | 3.99 | 3.87 | 3.78 | |
Support 3 (S3) | 3.71 | 3.88 | 3.76 | ||
Support 4 (S4) | 3.69 |